ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Rated “Moderate Buy” by Sell-Side Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $4.60.

Separately, Weiss Ratings upgraded ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th.

ALX Oncology Stock Performance

Shares of ALXO stock opened at $1.36 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.71 and a quick ratio of 9.71. The business has a fifty day moving average of $1.47 and a 200 day moving average of $1.82. The firm has a market capitalization of $188.06 million, a price-to-earnings ratio of -1.20 and a beta of 0.61. ALX Oncology has a 1 year low of $0.86 and a 1 year high of $2.66.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. As a group, research analysts expect that ALX Oncology will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On ALX Oncology

Several large investors have recently bought and sold shares of ALXO. venBio Partners LLC purchased a new position in ALX Oncology during the second quarter worth about $26,671,201. BlackRock Inc. acquired a new stake in ALX Oncology during the 2nd quarter valued at $15,317,000. Redmile Group LLC increased its position in ALX Oncology by 143.9% during the 1st quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock worth $15,968,000 after purchasing an additional 4,699,470 shares in the last quarter. Vivo Capital LLC acquired a new stake in ALX Oncology during the first quarter worth approximately $6,385,000. Finally, 5AM Venture Management LLC purchased a new stake in ALX Oncology in the 2nd quarter worth approximately $6,328,663. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company’s research centers on the CD47-SIRPα pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system.

ALX Oncology’s lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments.